Navigation Links
Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
Date:12/4/2012

ANAHEIM, Calif., Dec. 4, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on December 14, 2012.  The dividend will be paid in lieu of the Company's regular quarterly cash dividend that would have been paid in the first quarter of 2013, and is scheduled to be paid on or about December 21, 2012.  The Company accelerated payment of the first quarter 2013 dividend to allow its shareholders to benefit from the current dividend tax rate that is scheduled to expire on December 31, 2012.  Future dividends will be at the discretion of the Board of Directors.

"Our business continues to grow and this dividend reflects our positive outlook and confidence in our ability to continue to generate returns for shareholders and invest in future growth through R&D," said Don M. Bailey, President and CEO of Questcor.

About Questcor 

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... acquisition of leading OTC brands from GSK in an ... is a clear demonstration of Perrigo,s unique ability to ... network spanning 36 countries.  Perrigo Chairman, ... "We are excited to complete this transaction, which clearly ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... PharMEDium Healthcare Corporation has become an Industry Supporter of ... of a new Corporate Supporter program available to pharmaceutical, ... N. Jonas, PharMEDium Chairman and CEO commented, "We are ... field through leadership, education and research.  As a leading ...
... FAIRFAX, Va., April 11, 2011 General Dynamics ... (NYSE: GD ), has been awarded ... training instrumentation suite into the Vincennes University hospital ... a realistic training environment for the continuing education ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2General Dynamics' InForce™ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ... the new Global Communications Director for InHealth Media. Mr. Spector comes with ... last 16 years doing on-air television, producing shows, on air-radio and media relations. ...
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees to ... InHealth media is a global sales and communications firm that offers U.S. brands a ... our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional needs ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... , ... August 30, 2015 , ... Rio Salado ... to serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, ... to help the college expand its reach and impact through innovative technologies and strategies. ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4
... Calif. (October 20, 2012) African American women who develop ... risk of developing diabetes in the future compared to white ... Permanente study published online in the journal Diabetologia . ... develop GDM during pregnancy. But for those who were diagnosed ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, Oct. ... the best time to begin AIDS drug treatments in HIV-positive ... common in Africa. Starting the drugs earlier, even by a ... are very sick, the research suggests. The cost ...
... News) -- ,Some of the genetic traits that give ... researchers. The findings will help efforts to understand ... provide molecular markers for surveillance. "Different bedbug populations ... in their levels of resistance and resistance strategies, so ...
... (HealthDay News) -- An antiseizure drug called primidone (Mysoline) ... are the most effective medicines to treat shaking in ... guideline from the American Academy of Neurology. Essential ... United States, is the most common type of tremor ...
... VA The Patient Protection and Affordable Care Act ... agenda for pragmatic and clinical trials that provide optimal ... October 2011 issue of Otolaryngology Head and Neck ... Drug Development recently reported that the median number of ...
... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... guidelines for cervical cancer testing for women, including when ... intervals between screenings and in some cases, supplementing the ... The American Cancer Society, the American Society for ...
Cached Medicine News:Health News:African-American women with gestational diabetes face high long-term diabetes risk 2Health News:Start HIV Drug Treatment Early in Patients With TB: Studies 2Health News:Start HIV Drug Treatment Early in Patients With TB: Studies 3Health News:New Guidelines Issued for Common Tremor Disorder 2Health News:Evidence-based medicine in health-care reform 2Health News:U.S. Cancer Groups Release Their Own Cervical Cancer Screening Guidelines 2Health News:U.S. Cancer Groups Release Their Own Cervical Cancer Screening Guidelines 3
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
Medicine Products: